Eric Morgen - 17 Feb 2026 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)

Role
Chief Operating Officer, Director
Signature
/s/ Dov A. Goldstein as attorney-in-fact
Issuer symbol
BIOA
Transactions as of
17 Feb 2026
Net transactions value
$0
Form type
4
Filing time
19 Feb 2026, 16:40:40 UTC
Previous filing
25 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Morgen Eric Chief Operating Officer, Director C/O BIOAGE LABS, INC., 5885 HOLLIS STREET, SUITE 370, EMERYVILLE /s/ Dov A. Goldstein as attorney-in-fact 19 Feb 2026 0002036289

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIOA Stock Option (Right to Buy) Award $0 +110,000 $0.000000 110,000 17 Feb 2026 Common Stock 110,000 $19.63 Direct F1
transaction BIOA Stock Option (Right to Buy) Award $0 +12,500 $0.000000 12,500 17 Feb 2026 Common Stock 12,500 $19.63 By Spouse F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F2 The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the holder's continued service to the Issuer on each vesting date.
F3 Represents an employee stock option directly held by the reporting person's spouse.